[1] 国际尿控协会.国际尿控学标准化指南[M].北京:人民卫生出版社,2011.
[2] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society[J]. Neurourol Urodyn, 2002,21(2):167-178. DOI: 10.1002/nau.10052.
[3] 那彦群,叶章群,孙光.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2011:147-153.
[4] Campbell J, Reid J, Ordon M, et al. The utilization of benign prostatic hyperplasia and bladder-related medications after a transurethral prostatectomy[J]. Urology, 2019, 130:126-131. DOI: 10.1016/j.urology. 2019.05.003.
[5] Kim SJ, Al Hussein Alawamlh O, Chughtai B, et al. Lower urinary tract symptoms following transurethral resection of prostate[J]. Curr Urol Rep, 2018, 19(10):85. DOI: 10.1007/s11934-018-0838-4.
[6] Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study[J]. BJU Int, 2006, 97(4):734-741. DOI: 10.1111/j.1464-410X.2006.06110.x.
[7] 胡龙芳.中老年男性下尿路症状现况调查及其危险因素分析[D].杭州: 浙江大学,2018.
[8] McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread[J]. Am J Surg Pathol, 1988, 12(12):897-906. DOI: 10.1097/00000478- 198812000-00001.
[9] Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group[J]. Urology, 1999, 53(3):473-480. DOI: 10.1016/s0090-4295(98)00654-2.
[10] Roehrborn CG, McConnell JD, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes[J]. Eur Urol, 2002, 42(1):1-6. DOI: 10.1016/s0302-2838(02)00210-5.
[11] McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group[J]. N Engl J Med, 1998, 338(9):557-563. DOI: 10.1056/NEJM199802263380901.
[12] Gupta N, Rogers T, Holland B, et al. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial[J]. J Urol, 2018, 200(2):405-413. DOI: 10.1016/j.juro.2018.02.3088.
[13] Enemchukwu E, Cameron A. Management of complex OAB patients: a call to action[J]. Neurourol Urodyn, 2022, 41(8):1938-1939. DOI: 10.1002/nau.25048.
[14] Petros P. The emperor has no clothes: OAB can be cured surgically[J]. Int Urogynecol J, 2022, 33(5):1043-1044. DOI: 10.1007/s00192-022-05130-8.
[15] Thorpe A, Neal D. Benign prostatic hyperplasia[J]. Lancet, 2003, 361(9366):1359-1367. DOI: 10.1016/S0140- 6736(03)13073-5.
[16] Elterman D, Bach T, Rijo E, et al. Transfusion rates after 800 Aquablation procedures using various haemostasis methods[J]. BJU Int, 2020, 125(4):568-572. DOI: 10.1111/bju.14990.
[17] 苏维.经皮神经肌肉电刺激治疗前列腺手术后尿失禁的疗效观察[D].广州: 南方医科大学,2021.DOI:10.27003/d.cnki.gojyu.2021.000544.
[18] 蔡翔.良性前列腺增生患者术后早期下尿路症状影响因素研究[D].遵义:遵义医科大学,2021.DOI:10.27680/d.cnki.gzyyc. 2021.000322.
[19] 崔占武,赵建中.膀胱过度活动症治疗药物临床研究进展[J].中国临床药理学杂志,2021,37(4):473-478.DOI:10.13699/j.cnki.1001-6821.2021.04.031.
[20] 徐其涛,罗娜,姜俊海,等.肉毒素A治疗神经源性膀胱过度活动症的系统评价[J].现代泌尿外科杂志,2015,(4):218-224.DOI:10.3969/j.issn.1009-8291.2015-04-003.
[21] 俞旭君,高庆和.慢性前列腺炎中西医结合多学科诊疗指南[J].中华男科学杂志,2020,26(4):369-376.DOI:10.13263/j.cnki.nja.2020.04.015.
[22] Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline[J]. J Urol, 2018, 200(3):612-619. DOI: 10.1016/j.juro.2018.05.048.
[23] Varkarakis I, Kyriakakis Z, Delis A, et al. Long-term results of open transvesical prostatectomy from a contemporary series of patients[J]. Urology, 2004, 64(2):306-310. DOI: 10.1016/j.urology.2004.03.033.
[24] Zhao YR, Liu WZ, Guralnick M, et al. Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction[J]. Int J Urol, 2014, 21(10):1035-1040. DOI: 10.1111/iju.12482.
[25] 李浩冉,陈敏,钟贺,等.经皮胫神经电刺激与M受体阻滞剂治疗膀胱过度活动症疗效和安全性的Meta分析[J].中华泌尿外科杂志,2022,43(3):212-216.DOI:10.3760/cma.j.cn112330-20210511-00263.
[26] 刘祎,陈先国.慢性前列腺炎相关免疫机制研究进展[J].中华男科学杂志,2017,23(7):652-655.DOI:10.13263/j.cnki.nja.2017.07.014.
[27] 万小萍,廖利民.可植入式胫神经刺激器治疗膀胱过度活动症的研究进展[J].临床泌尿外科杂志,2022,37(2):150-155.DOI:10.13201/j.issn.1001-1420.2022.02.015.
|